Yan LN, Wang W, Li B, Lu SC, Wen TF, Lin QY, Zeng Y, Cheng NS, Zhao JC, Dai YM. Single-dose daclizumab induction therapy in patients with liver transplantation.
World J Gastroenterol 2003;
9:1881-3. [PMID:
12918145 PMCID:
PMC4611568 DOI:
10.3748/wjg.v9.i8.1881]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).
METHODS: A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.
RESULTS: Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74%) than those in the control group (12 of 31, 38.71%), which were proved by pathologic diagnosis (P < 0.05). The incidence of infection at the early stage was not significantly different between two groups.
CONCLUSION: Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.
Collapse